Upload
shauna-ryan
View
214
Download
0
Embed Size (px)
Citation preview
IP management@universities 2014Best practices: Univ-Ind collaborations
Jo Bury, managing director VIB
Istanbul, October 30th-31st, 2014
Policy factors impacting innovation: The case of FlandersJo Bury, managing director VIB
Flanders anno 1994
• well established support for R&D• good (life) science• stars of worldclass
Flanders anno 1994
• well established support for R&D• good (life) science• stars of worldclass• Innogenetics – Plant Genetic Systems
How can we do better?
SWOT analysis Flanders 1994
• S: - strong science base (champions)• W: - no structural funding
- brain drain- no tech transfer
• O: - develop an attraction pole of excellence- build a knowledge economy
• T: - loose leading position
Benchmarks
• Max Planck Society• MRC UK• Karolinska Institutet• Cold Spring Harbor Labs• Salk Institute• HHMI
Preliminary conclusions
• Focus on excellence• PI vs Dir as DMU• Combine strenghts• Build critical mass• Build a tech transfer pipeline• Develop a biotech cluster
Business plan
• build a new institute from scratcho attract the champions
↕• reunite the champions in 1 SRC
o multisiteo stringent selection
Business plan (2)
• thematic focus:o GE: molecular mechanism of life
• high level of ambition:o top 10% WW
• continuous improvement:o selection / continuation based on excellence
• institution:o not another granting body
Business plan (3)
• long term financial commitment:o significant (30-50%)o 22 M€/yearo 5 yearso renewable (if excellent)
• stringent selection of university departments:o 9/100
• independent structure (SRC):o board of directorso own facilities (TTO)
Reduction to practice
• Minister-President:o visionary (long term view)o right combination of powerso April 1994
• government of Flanders:o April 1995
• foundation by notarial deed:o July 1995
• operations:o January 1996
Reduction to practice (2)Partnership with universities
• university campus• empower univ staff with VIB staff• framework agreement VIB-univ• mutual added value• share return on investment
– Publications: 2 affiliations– IPR: joint IP (VIB in charge)
VIB today
VIB: Mission
To create groundbreaking knowledge on the molecular mechanisms ruling life for the benefit of scientific progress and the benefit of society
Excellence in science+
Excellence in tech transfer
VIB state of affairs
• multisite institute (JV with univ)• 1350 scientists – technicians (50/50)• 76 research groups• 8 departments• management agreement (2012-2016)
• 43.8 M€/year• 5 years• key performance indicators
Basic Research@VIBMolecular mechanisms
• molecular medecine– normal growth and development– health vs disease
neurobiology cancer inflammation cardiovascular
• molecular farming– normal growth and development– normal vs stress
Basic Research@VIB
• centre of excellence• important biological questions• stimulating environment
– VIB grant– research infrastructure– disruptive technologies– dialective environment– institutional integration
Science policyMaking the Difference
• frontline (not me too)• world class (international competition)• relevance + quality
good record of high impact publications and patent applications
performance
=
Results 2013
Results 2013
• 620 peer reviewed publications• 168 breaktrough articles (68 T1%)• 70 PhD’s
Publications in top journals (T5%)
'95 '96 '97 '98 '99 '00 '01 '02 '03 '04 '05 '06 '07 '08 '09 '10 '11 '12 '130
20
40
60
80
100
120
140
160
180
Excellence in tech transfer
An integrated and pro-active team
IP Management
Business Development New Ventures
License & BD deals
AssessmentTT Projects
Start-up Projects
Licensing case Start-up case
A proactive IP strategy
0
5
10
15
20
25
30
35
40
4595 96 97 98 99
2000 '0
1'0
2'0
3'0
4'0
5'0
6'0
7'0
8'0
9 10 11 12 13
non-VIB
VIB
• VIB patent estate: 218 patent families
116 partnering agreements signed
95 96 97 98 99 00 '01 '02 '03 '04 '05 '06 '07 '08 '09 10 11 12
VIB 0 8 8 15 15 34 29 47 65 61 69 59 82 80 94 111 124 116
0
20
40
60
80
100
120
140
VIB integrated approach towards start-ups
Evaluate technology & business opportunity
Build IPR platformPerform FTO analysis
Conceptualize and write business plan
Facilitate start-up and early stage
Search for managementRoad show to
investors
VIBPOC Fund
Seed Capital Fund
VIB start-ups: from knowledge to products
608 employees
8 M€
5 M€
5 M€
14.5 M€
20 M€
2 M€
2 M€
5 M€
+ 29 M€ => IPO => Tradesale
+ 25 M€ + 11 M€ => Tradesale
+ 25M€ + 40 M€ => IPO
+ 7.9 M€ + 5.1 M€
+ 15.5 M€ + 10.7M€
+ 5.5M€
VIB start-ups: equity investment and exit
• Total investment in VIB start-ups (€)
– VC/private : 255.200.000– IPO/PIPE/SPO : 272.500.000
527.700.000
~ 50% international
VIB start-ups: a magnet for foreign investments
Products: therapeutic pipeline
• 13 therapeutics under development, including 1 small compound
VIB as facilitator for the biotech sector
Infrastructure
Attracting/consolidatingcompanies to/in Flanders
Building networks
Bio-incubator Leuven
34
UGent Technology Park: Large Cluster in Biotechthe largest R&D hub in AgBio in Europe
DevGen
arGEN-X
Bayer Crop Science
(former PGS)
VIB/UGent
VIB BioincubatorActogenix, ADX Neuroscience,
Biomaric, BIP, Complix, Pronota, Seps Pharma, Yakult,
Q-Biologicals
Bioaccelerator I
Bioaccelerator II
Ablynx
InnogeneticsIIC Ugent
Oxyrane, Genohm,
Biogazelle, Feops, Com & Sciense, Quinvita, Bio-
ActorCropDesign
Anabiotec
Fytolab
1900 employees
Ghent Agrobiotech cluster
Ghent Biomed campus
From science to value
Policy factors impacting innovation: The case of FlandersJo Bury, managing director VIB
Science policy (2)Making the right Choices
• selecting on excellence• bottom up approach• strategic plan (15.10)• exposure to SABs• monitoring (w y m i w y g)• evaluation• reward excellence (rotation)• VIB grant allocation ~ performance